CL2020000733A1 - Proteína de fusión que comprende una porción de fgf-18. - Google Patents

Proteína de fusión que comprende una porción de fgf-18.

Info

Publication number
CL2020000733A1
CL2020000733A1 CL2020000733A CL2020000733A CL2020000733A1 CL 2020000733 A1 CL2020000733 A1 CL 2020000733A1 CL 2020000733 A CL2020000733 A CL 2020000733A CL 2020000733 A CL2020000733 A CL 2020000733A CL 2020000733 A1 CL2020000733 A1 CL 2020000733A1
Authority
CL
Chile
Prior art keywords
fgf
fusion protein
cartilage
osteoarthritis
fused
Prior art date
Application number
CL2020000733A
Other languages
English (en)
Inventor
Anne Gigout
Christian Brenneis
Thomas Rysiok
Stefan Zielonka
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of CL2020000733A1 publication Critical patent/CL2020000733A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A NUEVAS PROTEÍNAS DE FUSIÓN QUE COMPRENDEN UNA PORCIÓN DE FGF-18 FUSIONADA A UNA PORCIÓN ANTI-NGF. DICHA PROTEÍNA DE FUSIÓN PUEDE SER UTILIZADA PARA EL TRATAMIENTO DEL DESORDEN DE UN CARTÍLAGO TAL COMO OSTEOARTRITIS O DAÑO AL CARTÍLAGO.
CL2020000733A 2017-09-21 2020-03-20 Proteína de fusión que comprende una porción de fgf-18. CL2020000733A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17192467 2017-09-21
EP18182696 2018-07-10

Publications (1)

Publication Number Publication Date
CL2020000733A1 true CL2020000733A1 (es) 2020-10-02

Family

ID=63557503

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020000733A CL2020000733A1 (es) 2017-09-21 2020-03-20 Proteína de fusión que comprende una porción de fgf-18.

Country Status (15)

Country Link
US (1) US11572395B2 (es)
EP (1) EP3684791A1 (es)
JP (1) JP7237945B2 (es)
KR (1) KR20200054300A (es)
CN (1) CN111132997A (es)
AU (1) AU2018337686B2 (es)
BR (1) BR112020005035A2 (es)
CA (1) CA3074483A1 (es)
CL (1) CL2020000733A1 (es)
IL (1) IL273271A (es)
MX (1) MX2020003211A (es)
PH (1) PH12020550099A1 (es)
RU (1) RU2020113713A (es)
SG (1) SG11202001772SA (es)
WO (1) WO2019057805A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX386014B (es) 2016-08-10 2025-03-18 Univ Ajou Ind Academic Coop Found Citocina fusionada a fc heterodimérico, y composición farmacéutica que comprende la misma.
AU2019366956B2 (en) * 2018-10-23 2025-10-30 Dragonfly Therapeutics, Inc. Heterodimeric Fc-fused proteins
CN113151185B (zh) * 2020-11-17 2023-06-23 苏州仁端生物医药科技有限公司 分泌抗fgf18单克隆抗体杂交瘤细胞株及其单抗、应用
EP4384218A4 (en) * 2021-08-09 2025-11-05 Merck Patent Gmbh Proteins that uncouple T-lymphocyte-mediated tumor cytotoxicity from the release of pro-inflammatory cytokines
CN117721115A (zh) * 2022-09-06 2024-03-19 深圳瑞吉生物科技有限公司 用于治疗骨关节炎的mRNA及其制备方法与应用
EP4720122A1 (en) * 2023-06-05 2026-04-08 Pure Biologics Spólka Akcyjna Anti-garp antibodies and methods of use

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA75316C2 (uk) 1996-10-16 2006-04-17 Займодженетікс, Інк. Гомологи з фактором росту фібробласта
US7470665B2 (en) 1999-12-02 2008-12-30 Zymogenetics, Inc. Methods for targeting cells that express fibroblast growth receptor-3 or -2
US6855510B2 (en) * 2001-03-20 2005-02-15 Dana Farber Cancer Institute, Inc. Pharmaceuticals and methods for treating hypoxia and screening methods therefor
PT1454138E (pt) * 2001-12-04 2012-03-28 Merck Patent Gmbh Imunocitoquinas com seletividade modulada
AU2003279835B2 (en) 2002-10-07 2009-09-10 Zymogenetics, Inc. Methods of administering FGF18
CN1980952A (zh) * 2004-02-23 2007-06-13 伯瑞恩药物私人有限公司 多聚化hiv融合抑制物
US8871912B2 (en) 2006-03-24 2014-10-28 Merck Patent Gmbh Engineered heterodimeric protein domains
HRP20120643T1 (hr) * 2006-08-25 2012-08-31 Ares Trading S.A. Liječenje poremećaja hrskavice sa fgf-18
CN101993485B (zh) * 2009-08-20 2013-04-17 重庆富进生物医药有限公司 促胰岛素分泌肽类似物同源二聚体及其用途
US9505829B2 (en) * 2010-08-19 2016-11-29 Zoetis Belgium S.A. Anti-NGF antibodies and their use
RU2678810C2 (ru) 2014-02-02 2019-02-01 Медиммун Лимитед ХИМЕРНЫЙ БЕЛОК, СОСТАВЛЕННЫЙ ИЗ ДОМЕНА АНТАГОНИСТА NGF И ДОМЕНА АНТАГОНИСТА TNFα
ES2935274T3 (es) 2014-12-05 2023-03-03 Merck Patent Gmbh Anticuerpo con intercambio de dominios
BR112018002404A2 (pt) 2015-08-13 2018-09-18 Merck Patent Gmbh composição de combinação compreendendo composto de fgf-18

Also Published As

Publication number Publication date
IL273271A (en) 2020-04-30
AU2018337686A1 (en) 2020-03-19
JP2020536511A (ja) 2020-12-17
EP3684791A1 (en) 2020-07-29
CA3074483A1 (en) 2019-03-28
US20200299347A1 (en) 2020-09-24
AU2018337686B2 (en) 2023-04-20
BR112020005035A2 (pt) 2020-09-15
JP7237945B2 (ja) 2023-03-13
WO2019057805A1 (en) 2019-03-28
RU2020113713A3 (es) 2022-03-03
CN111132997A (zh) 2020-05-08
US11572395B2 (en) 2023-02-07
PH12020550099A1 (en) 2020-09-14
SG11202001772SA (en) 2020-04-29
RU2020113713A (ru) 2021-10-21
MX2020003211A (es) 2020-09-21
KR20200054300A (ko) 2020-05-19

Similar Documents

Publication Publication Date Title
CL2020000733A1 (es) Proteína de fusión que comprende una porción de fgf-18.
CY1124309T1 (el) Τροποποιημενα πολυπεπτιδια fgf-21 και χρησεις εξ αυτων
CY1122415T1 (el) Κυκλοπροπυλαμινες ως lsd1 αναστολεις
CY1122803T1 (el) Διαδικασιες γραμμης παραγωγης σπορων και χρησεις αυτων
MX2024001192A (es) Anticuerpos anti gen 3 de activacion linfocitica (lag-3) y metodos para usarlos.
MX2019009812A (es) Proteinas quimericas basadas en tigit y light.
CL2017001369A1 (es) Proceso para manipular el nivel del contenido de glicano de una glicoproteina
CL2017001584A1 (es) Anticuerpos antimiostatina, polipéptidos que contienen regiones fc variantes, y métodos de uso
CL2017001204A1 (es) Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteína quinasa
MX2017014822A (es) Composiciones y métodos para la reprogramación del tcr con proteínas de fusión.
MX391249B (es) Anticuerpos anti-muc16 y sus usos.
MX2016009625A (es) Proteinas quimericas tipo fosfatasa alcalina.
EA201691594A1 (ru) Циклопропиламины в качестве ингибиторов lsd1
IL259690B (en) Use of c-type natriuretic peptide variants to treat osteoarthritis
MX2017006448A (es) 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de receptor acoplado a proteina g 139 (gpr139).
MX387560B (es) Procedimiento para mejorar la solubilidad de proteínas y péptidos usando un enlace del fragmento fc de inmunoglobulina.
MX373818B (es) Composiciones de apilimod y métodos para usar las mismas.
MX2016013849A (es) Un factor de secrecion de proteinas con alta eficacia secretora y un vector de expresion que lo comprende.
MX2016014144A (es) Composiciones de proteina concentrada y metodos para su elaboracion y uso.
PL3226854T3 (pl) Kompozycja na bazie aminokwasów do odbudowy fibroelastyny w tkance łącznej skóry
CL2017000087A1 (es) Un proceso novedoso para la purificación de rhu-gcsf
CL2017003144A1 (es) Péptidos lipidados resistentes a proteasas
MX2019013124A (es) Proteinas de fusion de inhibidor de tripsina urinaria (uti).
SG11202000775SA (en) Fusion tags for recombinant protein expression
MX2018003445A (es) Expresion de proteinas que contienen fc.